Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif. , May 15, 2024 /PRNewswire/ --Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc.
MENLO PARK, Calif. , May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024 . First quarter results: Revenue of $38.8 million compared with $38.9 million in the prior-year period. Instrument revenue of $19.0 million compared
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended
HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology , Mental and Reproductive Health , Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif.
MENLO PARK, Calif. , March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an
HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget
MENLO PARK, Calif. , Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference
MENLO PARK, Calif. , Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023 . Fourth quarter results Revenue of $58.4 million , a 113% increase compared with $27.4 million in the prior-year period.
New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™ Sequencing System MENLO PARK, Calif. , Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library
MENLO PARK, Calif. , Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024 , at 5:00 pm Eastern Time . The call will be webcast and may be accessed